评估肺结核的快速诊断检验
|
By LabMedica International staff writers Posted on 02 May 2018 |

图片:Xpert MTB/RIF试剂载入GeneXpert 4模块仪器(图片蒙Cepheid公司惠赐)。
在资源有限的场合诊断涂片阴性肺结核与肺外结核(TB)仍是一项挑战。确认涂片阴性与肺外结核病例需要阳性的结核分枝杆菌培养物,需要长达八周时间制备。
研究人员评估了是否能实现用商用的快速分子诊断检验日常诊断涂片阴性或肺外的结核,评估了其诊断准确度,还评估了现实场合HIV的患病率。
一组来自多国的科学家与瑞士日内瓦大学医院(www.hug-ge.ch)的科学家合作,在两年期间开展了一项前瞻性队列研究,相继纳入了疑似涂片阴性肺结核/肺外结核的所有病例。将病例分为四类:确实、很可能、可能有结核或有其它诊断结果。在马达加斯加的一家当地医院对疑似肺结核患者的痰液样本进行齐尔-尼尔森染色后直接做显微镜检。
来自肺结核患者和肺外结核患者的所有的抗酸杆菌(AFB)阴性涂片都被送到结核分枝杆菌实验室做二次涂片检查、培养,并用美国加利福尼亚州森尼韦尔市Cepheid股份有限公司(www.cepheid.com)的Xpert MTB/RIF进行筛查。生物液(脑脊液、腹膜液、胸腔积液)的标准分析(细胞学分析与生化分析),还对组织样本(淋巴结、皮肤活检样本、胸腔活检样本和滑膜活检样本)做了病理检查。对所有患者进行HIV血清检验。通过三种不同的构象快速检验证实了HIV的状态。
科学家发现,纳入研究的363名患者中,183人(50.4%)有疑似的涂片阴性肺结核,180人(49.6%)有疑似的肺外结核。用Xpert MTB/RIF检测经过证实的病例,灵敏度、特异性、阳性预测值、阴性预测值分别为82.4%、98.8%、98.3%和86.6%;如果把经过证实的病例和可能性大的病例一起算,这些值分别为65%、98.8%、98.5%和64%。肺外结核的诊断准确度略低于涂片阴性的肺结核。HIV感染的患病率为12.1%,但是几乎半数病例没有结核(其它诊断结果组)。
该研究的论文发表于2018年4月号的《国际传染病杂志》(International Journal of Infectious Diseases)。作者总结说,在资源贫乏场合实施结核的快速诊断是可行的。Xpert-MTB/RIF检测难诊人群的性能十分突出。这项研究得出的HIV患病率远高于所报的马达加斯加大众的患病率、结核患者的患病率以及结核以外病症患者的患病率。
日内瓦大学医院>>> www.hug-ge.ch
Cepheid >>> www.cepheid.com
Latest 实验室技术 News
Channels
Clinical Chemistry
view channel
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read more
Urine-Based Test Shows Promise for Autism Screening in Children
Autism spectrum disorder (ASD) is commonly diagnosed through behavioral assessments, which can involve long waits that delay intervention. Earlier identification is linked to better developmental outcomes,... Read moreMolecular Diagnostics
view channel
Blood-Based Assay Enables Noninvasive Monitoring of Sarcoma Immunotherapy Response
Sarcomas remain difficult to monitor during immunotherapy, as low tumor mutation burden can limit traditional circulating tumor DNA approaches and repeat tissue biopsies are often impractical in advanced disease.... Read more
Tumor Mutation Marker Helps Refine Lung Cancer Prognosis and Guide Therapy Selection
Lung cancer remains the leading cause of cancer death worldwide, while heterogeneous tumor genetics continue to complicate treatment decisions. Although molecular testing is increasingly used to match... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
Gut Microbiome Signatures Help Identify Risk of IBD Progression
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read morePathology
view channel
AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
Tertiary lymphoid structures are emerging as important indicators of antitumor immunity, but their heterogeneity and spatial context within tumors remain difficult to capture through routine diagnostics.... Read more
AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel








